Jonathan Walbaum

Cochrane updated its PSA screening meta-analysis. 789,086 men across 6 RCTs. ➡️ PCa-specific mortality: rate ratio 0.87 (moderate certainty) ➡️ Metastatic diagnosis: RR 0.65 ➡️ Adverse events / QoL: little to no difference Why this matters: 💡 PSA screening is back on stronger evidentiary footing for disease-specific mortality. Shared decision making still drives the recommendation downstream and additional tools (biomarkers and MRI) continue to improve the gap. bit.ly/CochranePSA2026 @EBMUrology #ProstateCA #Screening #Cochrane #GUonc #AUA26

Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bj… Review synthesises international guidance on lutetium-177 PSMA radioligand therapy (177Lu-PSMA-RLT) in #ProstateCancer , focusing on metastatic castration-resistant disease. Major societies, including EAU, NCCN, ASCO, AUA/SUO, and CUA, endorse 177Lu-PSMA-617 after prior ARPI and taxane therapy, supported by VISION and TheraP trial data. Emerging evidence from PSMAfore is expanding use into earlier treatment settings. Current recommendations emphasise PSMA-positive patient selection, standardised dosing, androgen deprivation therapy continuation, and multidisciplinary management. @declangmurphy @DrMHofman @AzadOncology @RenuEapen @lawrentschuk @drMPerera @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Back from an amazing @APCCC_Lugano! Special thanks to @gu_onc for the GU Cast Travel Grant and their support of the next gen of Urology! Grateful for the opportunity Inspired by new ideas, friends and connections A pleasure meeting @UroTeragLATAM and fellow Chilean colleagues

The #APCCC5k at #APCCC26 🇨🇭 if you didnt make it, see you at #APCCC5k in 2027‼️ @DBarreiro4 @jonwalbaum @roodvdb @AnthonyMJoshua @julired3 @swoo_rad @docheinrich @ProfKHerrmann @AarmstrongDuke Shout out to the awesome @declangmurphy @APCCC_Lugano @Silke_Gillessen @AOmlin @weoncologists @declangmurphy @RenuEapen @DrYukselUrun @nataliagandur @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @dmukherji @Uromigos

⭐ #APCCC26 Day 1 Preview — Setting the stage for key clinical decisions in prostate cancer @OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin 🔹 Welcome & opening With @Silke_Gillessen and @AOmlin 🔹 Session 1 — High-risk & locally advanced prostate cancer Chairs: Pierre Blanchard and Edward Schaeffer Key voices today: André Deschamps, Glen Kristiansen, Derya Tilki, @ChrisSweens1, Jeff Michalski, @BertrandTOMBAL, @declangmurphy, Jason A. Efstathiou and @DrRanaMcKay 🔹 Key questions: • Are we overtreating in the mpMRI / PSMA PET era? • Which patients need ARPI + RT + long-term ADT? • When may surgery alone be enough? • Can genomics / AI help reduce over- and undertreatment? • How should we treat older patients with high-risk disease? 🔹 Session 2 — PSA recurrence / persistence Chairs: Neal Shore and Valerie Fonteyne With Erik Briers, Jochen Walz, Pierre Blanchard, @piet_ost, @DrSpratticus, Phil Cornford, Edward Schaeffer, @KOSJ12 and Valerie Fonteyne 🔹 Key questions: • PSA persistence or recurrence after RP — when and how to act? • PSA recurrence after RT — when and how to act? • Early salvage RT vs adjuvant RT • Who may avoid imaging or treatment? • When is metastasis-directed therapy enough? 🔹 Session 3 — mHSPC management Chairs: Darren M. C. Poon and @ChrisSweens1 With Ana Aparicio, David Matheson, Susan Halabi, Ian D. Davis, @DrYukselUrun, Karim Fizazi / Robert J. Jones, @Tylersbrt, Joaquin Mateo and Shahneen Sandhu 🔹 Key questions: • What subgroups matter in mHSPC today? • Which endpoints matter most: rPFS, OS, QoL? • Who needs TRIPLET — and who is enough with DOUBLET? • What is the role of prostate RT? • How should we test molecular alterations? • Who should receive ARPI + PARPi or AKTi? 🔹 Take-home: Day 1 is all about clinical decision-making: who to treat, when to intensify, when to de-escalate — and how to personalize care. @declangmurphy @RenuEapen @DrYukselUrun @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb #ProstateCancer #UroOncology #Oncology

⭐ #APCCC26 Day 1 THE BIG CLINICAL QUESTIONS START TODAY @OncoAlert @APCCC_Lugano #APCCC26 @Silke_Gillessen @AOmlin Today’s agenda goes straight to the decisions we face every day in prostate cancer care: 🔹 Are we overtreating in the mpMRI / PSMA PET era? 🔹 Who really needs treatment intensification? 🔹 When can we safely de-escalate? 🔹 How should we manage PSA recurrence? 🔹 TRIPLET vs DOUBLET in mHSPC — for whom? 🔹 Can genomics, AI and biomarkers guide better decisions? 🔹 Key theme: Not only what treatment works — but who truly needs it, when, and for how long. @declangmurphy @RenuEapen @DrYukselUrun @fabioturco92 @UrsulaVogl @SScagliarini @Tylersbrt @neerajaiims @amerseburger @Cdanicas @AarmstrongDuke @BertrandTOMBAL @ChrisSweens1 @EAntonarakis @KOSJ12 @VedangMurthy @DrRanaMcKay @LoebStacy @stefanofanti4 @mirrorsmed @profkhermann @dr_coops @piet_ost @_ShankarSiva @DrSpratticus @scocmem @AmandaNizamMD @tompowles1 @brian_rini @Uromigos @EUplatinum @EANM_NucMed @ESTRO_RT @Uroweb #ProstateCancer #UroOncology #Oncology

It's Testicular Cancer Awareness Month! Do you know how your pair is hanging? Testicular cancer is the #1 cancer among young guys but it's highly curable when caught early. If you’ve got ’em, check your nuts. Head to movember.com/knowthynuts to learn how.

🚨The sequel is here!! The other 👞 drops. Cribriform morphology in ProtecT — now in prostatectomy specimens #ProstateCancer #radonc #UroSoMe @UroToday @APCCC_Lugano @PCF_Science @OncoAlert 🧵1️⃣

⚡️ NICE 2026 kidney cancer guideline (diagnosis & management) — updated pathway from suspicion → staging/biopsy → risk-adapted treatment & follow-up. Striking stat: 87% of UK stage 1a RCC is diagnosed incidentally, underscoring how hard early detection is in routine practice. #KidneyCancer @OncoAlert thelancet.com/journals/lanon…

Proud moment and HUGE news from #EAU26: #PRIMARY2 shows PSMA PET/CT can safely halve prostate biopsies in men with equivocal MRI, avoiding biopsy in 49% without missing cancer. uroweb.org/news/scan-that…

ICYMI, the GU Cast Live Show at #EAU26 in London now streaming on all our channels. What a fantastic evening with so many of our listeners/viewers. Thanks so much to @MaartenAlbersen @Uroweb for the invite. Enjoy the replay! @declangmurphy @RenuEapen youtu.be/XOf6ASyATmg?si…

Prof Hugosson: Göteborg trial with 30 year outcomes! NND falls to -6-, with greatest benefit for men 50-59 at randomization. Despite no image guidance, high overdx, and suboptimal tx. Best evidence we have re: the evidence for #prostatecancer screening. Get tested! #eau26 @uroweb

In October 2025 we presented our study on the impact of Public Health Policy for Testicular Cancer in Chile at Congreso @Urolchi 2026, demonstrating improved Overall Survival after implementation. We won best Oral presentation and today en route to #EAU26 thanks to this prize 🏆

🚨 #BladderCancer VESPER Secondary Analysis 🆕 European Urology Oncology 2026 @OncoAlert Basal/Squamous molecular subtype emerges as the strongest prognostic factor for OS after NAC + cystectomy N = 297 (central molecular review) 🔬 4 independent prognostic factors for overall survival: ▪ Creatinine clearance ▪ Lymphovascular invasion ▪ Perineural invasion ▪ Basal/Squamous (Ba/Sq) subtype 📊 5-year OS: ▫ 0 factors → 72% ▫ 1 factor → 67% ▫ ≥2 factors → 38% Ba/Sq subtype showed the highest prognostic value Independent of treatment arm (ddMVAC vs GC) 👉 Biological heterogeneity matters. 👉 Molecular stratification should inform perioperative strategy. As immunochemotherapy expands, overtreatment risk increases. Subtyping may help refine selection. 📖 Eur Urol Oncol 2026 doi.org/10.1016/j.euo.… @JFontugne Yves Allory Stephane Culine @HopSaintLouis @APHP @CancerParisNord #MIBC #MolecularSubtyping #PrecisionOncology #Neoadjuvant #GUoncology

It’s disappointing to me that TURBT continues to be dismissed as a “low-priority” procedure in so many training programs. This single step defines the entire course for a bladder cancer patient. Accurate diagnosis, precise staging, and the choice of therapy all hinge on a high quality TURBT. And the “advanced genomic analysis and molecular profiling” these same programs love to promote? It all begins with adequate, high-quality tissue obtained through a TURBT. Yet incomplete resections leave behind residual tumor in up to 78% of cases at restaging, leading to higher recurrence rates and unnecessary progression. If we are serious about improving outcomes in NMIBC - and even MIBC - we must treat TURBT with the respect it deserves: structured, deliberate training curricula, hands-on attending involvement, and real performance metrics. This is why the @IBCG_BladderCA will make this one of the focus topics of our retreat this year, #IBCG26 @UrogerliMD @JoshMeeks @bbmdmsk @siadaneshmand @RobertoContieri @paolo_gontero @ParamMariappan @joanfundi @jteoh_hk @spsutkaMD @WorldBladderCan @BladderCancerUS @drgaganprakash @SUO_YUO @veerukasi

In localized radiorecurrent #ProstateCancer, salvage focal therapy provided similar 10-year survival outcomes as radical prostatectomy but resulted in substantially fewer perioperative complications. ja.ma/4rMagw4

Now online! Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial by Roberto Contieri et al. Thank you to the authors for choosing #EUO to publish your work. Read the full article here: buff.ly/5gskvCp @uroweb @mroupret @jteoh_hk @Ric_Campi @CaPsurvivorship @UroDocAsh @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect @RobertoContieri

📰 Is audit enough to improve TURBT quality? Insights from the RESECT trial reveal improved outcomes, but can it be implemented in clinical routine? Commentary by Dr. Elisabeth Grobet-Jeandin (@elijeandin). #NMIBC #bladdercancer 👇 bladder.uroonco.uroweb.org/publication/re…

📅 Les compartimos el calendario anual de SCHU, que incluye nuestras actividades académicas oficiales, además de las iniciativas patrocinadas y las internacionales. Esperamos que puedan organizar y planificar sus agendas para que puedan participar en estas actividades.